Prevalence of molecular markers of anti-malarial drug resistance in Plasmodium vivax and Plasmodium falciparum in two districts of Nepal by Ranjitkar, Samir et al.
RESEARCH Open Access
Prevalence of molecular markers of anti-malarial
drug resistance in Plasmodium vivax and
Plasmodium falciparum in two districts of Nepal
Samir Ranjitkar
1, Mette L Schousboe
1, Thomas Thyge Thomsen
1, Madhav Adhikari
2, Christian MO Kapel
3,
Ib C Bygbjerg
1 and Michael Alifrangis
1*
Abstract
Background: Sulphadoxine-pyrimethamine (SP) and chloroquine (CQ) have been used in treatment of falciparum and
vivax malaria in Nepal. Recently, resistance to both drugs have necessitated a change towards artemisinin combination
therapy (ACT) against Plasmodium falciparum in highly endemic areas. However, SP is still used against P. falciparum
infections in low endemic areas while CQ is used in suspected cases in areas with lack of diagnostic facilities. This study
examines the prevalence of molecular markers of CQ and SP resistance in P. falciparum and Plasmodium vivax to
determine if high levels of in vivo resistance are reflected at molecular level as well.
Methods: Finger prick blood samples (n = 189) were collected from malaria positive patients from two high endemic
districts and analysed for single nucleotide polymorphisms (SNPs) in the resistance related genes of P. falciparum and
P. vivax for CQ (Pfcrt, Pfmdr1, Pvmdr1) and SP (Pfdhfr, Pfdhps, Pvdhfr), using various PCR-based methods.
Results and discussion: Positive P. vivax and P. falciparum infections were identified by PCR in 92 and 41 samples
respectively. However, some of these were negative in subsequent PCRs. Based on a few P. falciparum samples, the
molecular level of CQ resistance in P. falciparum was high since nearly all parasites had the Pfcrt mutant haplotypes
CVIET (55%) or SVMNT (42%), though frequency of the Pfmdr1 wild type haplotype was relatively low (35%).
Molecular level of SP resistance in P. falciparum was found to be high. The most prevalent Pfdhfr haplotype was
double mutant CNRNI (91%), while frequency of Pfdhps double mutant SGEAA and AGEAA were 38% and 33%
respectively. Combined, the frequency of quadruple mutations (CNRNI-SGEAA/AGEAA) was 63%. Based on P. vivax
samples, low CQ and SP resistance were most likely due to low prevalence of Pvmdr1 Y976F mutation (5%) and
absence of triple/quadruple mutations in Pvdhfr.
Conclusions: Based on the limited number of samples, prevalence of CQ and SP resistance at molecular levels in
the population in the study area were determined as high in P. falciparum and low in P. vivax. Therefore, CQ could
still be used in the treatment of P. vivax infections, but this remains to be tested in vivo while the change to ACT
for P. falciparum seems justified.
Background
Malaria is one of the major health problems in South-
East Asia where 1.3 billion people (76% of total popula-
tion) are at risk, causing around 120,000 deaths yearly
[1]. Plasmodium vivax malaria is the most widespread
and prevalent in this region but large knowledge gaps
still exits that preventing the assessment of the technical
feasibility of its elimination still exist [2]. In Nepal,
roughly 80% (22.5 million) of the population lives in
malaria endemic areas of which seven million reside in
highly endemic areas [3]. P. vivax is the predominant
species that causes around 80-90% of the total malaria
cases while Plasmodium falciparum is the main cause of
malaria epidemics in Nepal [4]. Malaria transmission
may occur throughout the year but mostly from March
to November with peaks in June, July and August [5].
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of P. vivax infections as well as for the treatment of sus-
pected P. falciparum infections in situations where diag-
nosis is unavailable; sulphadoxine-pyrimethamine (SP)
has been the drug of choice for laboratory confirmed
uncomplicated P. falciparum infections. Recently, arte-
misinin combination therapy (ACT) was introduced in
13 high endemic areas, replacing SP, as treatment for
laboratory confirmed uncomplicated P. falciparum due
to reports of high SP resistance [4].
Anti-malarial drugs have been one of the most impor-
tant tools in the control of malaria over the last 50 years
[6,7]. However, a major impediment to this strategy is the
capacity of the parasites to develop drug resistance. This
resistance has spread almost globally with regard to CQ
and SP [7,8]. In Nepal, CQ resistance to P. falciparum was
first observed in 1984, then in 1986, 1987 and 1988 [9].
CQ resistance in P. vivax has not been recorded. SP resis-
tance in P. falciparum was first recorded in 1996 and then
again in 2003 [9,10]. These studies were based on reports
of treatment failures. Molecular markers of drug resis-
tance, which are now commonly applied as an adjunct in
the surveillance of anti-malarial drug resistance, have had
only been used limited in Nepal. The advantage of using
molecular markers of drug resistance is that the level of
drug resistance can be studied retrospectively, such as
after a drug has been abandoned due to reports of high
levels of drug resistance in vivo.
CQ resistance is associated with single nucleotide poly-
morphisms (SNPs) in the P. vivax multidrug resistance
gene 1 (Pvmdr1) at codon (c) 976 (Y976F) [11] and the
P. falciparum chloroquine resistance transporter gene
(Pfcrt) at c76 (K76T) [12,13]. In P. falciparum,c e r t a i n
mutant haplotypes at c72-76 are highly prevalent glob-
ally, namely CVIET and SVMNT [14]. Additionally,
SNPs at c86, c184 and c1246 in P. falciparum mdr-1
(Pfmdr1) have been associated with CQ resistance [6,15].
However, its role is considered as modulatory when
SNPs in Pfmdr1 occur with the Pfcrt K76T mutation [7].
Resistance to SP is conferred by SNPs in the genes
coding for dihydrofolate reductase (dhfr) and dihydrop-
teroate synthetase (dhps) in both P. vivax [16,17] and
P. falciparum [18,19]. Although SP is not used deliber-
ately against P. vivax infections, exposure can occur
because mixed infections a r ec o m m o na n do f t e nm i s -
diagnosed in Asia [20-22]. In P. vivax,S N P sa tc 5 7
(F57L), c58 (S58R), c61 (T61M) and c117 (S117N) in
Pvdhfr are associated with pyrimethamine (PYR) resis-
tance [23,24]. For P. falciparum, SNPs at c51 (N51I),
c59 (C59R), c108 (S108N) and c164 (I164L) of Pfdhfr
are associated with PYR resistance [7,25] while sulpha-
doxine resistance is associated with SNPs at c436
(S436A), c437 (A437G), c540 (K540E), c581 (A581G)
and c613 (A613S/T) [8,25].
In Nepal, a limited study of molecular markers of anti-
malarial drug resistance only in P. falciparum has been
carried out [26]. Therefore, in light of the changing
drug policy in Nepal towards using ACT; artemether-
lumefantrine (AL) in some areas for P. falciparum and
to fill some of the gaps in the knowledge of resistance
to commonly used anti-malarials, the present study
investigated the prevalence of molecular markers of
anti-malarial drug resistance in both species by analys-
ing the SNPs of Pfcrt, Pfmdr1, Pfdhfr and Pfdhps in
P. falciparum and Pvmdr1 and Pvdhfr in P. vivax using
samples from patients living in two highly endemic dis-
tricts of Nepal.
Methods
Sample collection
Ethical clearance was obtained from the Nepal Health
Research Council, Kathmandu, for the study (Ref. No.
266). After obtaining informed consent from either the
patient or legal guardian, blood samples were collected
from patients attending private or government hospitals or
health posts in Jhapa (n = 146) and Banke (n = 43)
districts in Eastern and Western Nepal, respectively
(Figure 1). Malaria is highly endemic in both districts and
are two of the 13 districts where ACT (AL) was imple-
mented in 2004 [4]. These districts share borders with the
Indian states of Uttar Pradesh, Bihar and Assam where
malaria is endemic [5]. Finger prick blood samples were
collected either on Whatman no. 3 filter paper or as blood
smear slides from malaria positive patients confirmed by
microscopy or rapid diagnostic test.
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Figure 1 Distribution of malaria in Nepal. Distribution of malaria
in 75 districts of Nepal. Jhapa (1) and Banke (9) districts are the
study sites. High and low malaria endemic districts are categorized
on the basis of abundance of two principle vectors; Anopheles
minimus and Anopheles fluviatilis, and malaria transmission rate:
where annual malaria transmission rate are ≥ 1/1,000 and 0- 1/1,000
population respectively [5,53]. The figure has been modified from
[54] to provide more detail.
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Extraction of DNA from filter paper and blood smear
slides were done by chelex method as described in [27]
and [28] respectively. Plasmodium species (either vivax
or falciparum) were differentiated by nested polymerase
chain reaction (PCR) as in [29] and identification of
Plasmodium malariae and Plasmodium ovale were done
as previously [30]. Analysis of SNPs at Pvmdr1 was
done by sequencing the nested PCR products as in [31].
Analysis of SNPs at Pvdhfr was performed by sequence
specific oligonucleotide probes- enzyme-linked immuno-
s o r b e n ta s s a y( S S O P - E L I S A )a si n[ 3 2 ]a n df o rPfcrt,
Pfdhfr and Pfdhps, analysis were done by SSOP-ELISA
as previously described in [33]. Finally, Pfmdr1 was ana-
lysed by PCR-restriction fragment length polymorphism
(RFLP) as described elsewhere [34,35].
Results
Of the 189 samples, PCR identified 113 samples (60%)
positive for Plasmodium, of which 72 (64%) and 21
(19%) samples were P. vivax and P. falciparum respec-
tively while 20 (17%) of the samples carried mixed
P. falciparum/P. vivax infections (Table 1). No
P. malariae or P. ovale infections were detected. Posi-
tive samples from Banke were few (11%, n = 12) when
compared to Jhapa (89%, n = 101) and was pooled
since no apparent differences were observed between
the sampling sites. The species PCR positive samples
were further categorized according to type of infection,
gender and age group. The highest prevalence of
malaria was found in males (85%, n = 96) and the pre-
valence of infections were highest in the age group of
21-40 years (66%, n = 75) followed by 0-20 years (18%,
n=2 0 )( T a b l e1 ) .
Prevalence of SNPs in Pfcrt
The prevalence of haplotypes at c72-76 could be deter-
mined for 31 out of 41 P. falciparum positive samples
including mixed haplotypes (n = 2). The mutant haplo-
types CVIET and SVMNT were identified in 55% (n =
17) and 42% (n = 13) of samples respectively while 10%
samples (n = 3) contained the wild type CVMNK
(Figure 2).
Prevalence of SNPs in Pfmdr1
SNPs were examined at c86, c184 and c1246 in 33, 32 and
30 samples respectively. The prevalence of mutations in
the Pfmdr1 gene were N86Y (33%, n = 11) and Y184F
(44%, n = 14) including mixed infections (n = 1 for c86
and n = 3 for c184) while only wild type D1246 was
observed (n = 30). Haplotypes could be constructed for
three codons in 26 samples with different haplotypes iden-
tified: NYD (35%, n = 9), NFD (35%, n = 9) and YYD
(30%, n = 8) (Figure 3).
Prevalence of SNPs in Pfdhfr and Pfdhps
For Pfdhfr, SNPs were examined at c50, c51, c59, c108
and c164 in 32 samples. Mutations were determined at
N51I, C59R and S108N with the prevalence of 6% (n =
2), 97% (n = 31) and 97% (n = 31), respectively while
only wild types were detected at c50 (n = 32) and c164
(n = 32). Haplotypes could be constructed for 32 sam-
ples and determined as either double mutants CNRNI
(91%, n = 29), triple mutants CIRNI (6%, n = 2) and
wild type CNCSI (3%, n = 1) (Figure 4).
SNPs at c436, c437, c540 were examined in 30 sam-
ples and at c581 and c613 in 31 samples of the Pfdhps
gene, respectively. Majority of infections carried muta-
tions at A437G (77%, n = 23), K540E (70%, n = 21) and
S436A (33%, n = 10) while the A581G mutation was
found in 3% of samples (n = 1) and wild type was
observed only at c613 (n = 31). Haplotypes could be
constructed for 28 samples, of which double mutants
SGEAA (38%, n = 10) and AGEAA (33%, n = 9) were
the major haplotypes, followed by wild type SAKAA
Table 1 Distribution of PCR positive samples from Jhapa
and Banke districts in Nepal
Type of
infection
Gender Total Age group
Male Female 0-20 yrs 21-40 yrs ≥41 yrs
Pv 61(89%) 8(11%) 72(64%) 11(15%) 49(68%) 12(17%)
Pf 14(67%) 7(33%) 21(19%) 7(33%) 13(62%) 1(5%)
Pv+Pf 18(90%) 2(10%) 20(17%) 2(10%) 13(65%) 5(25%)
Total 96(85%) 17(15%) 113 20(18%) 75(66%) 18(16%)
Distribution of 113 positive samples based on species PCR according to
infected species: Pv = P. vivax,P f=P. falciparum and Pv+Pf = mixed
infections, along with the gender and age group of the subjects.
Figure 2 Prevalence of haplotypes of Pfcrt in samples from
Jhapa and Banke districts in Nepal. Prevalence of haplotypes at
codons 72-76 of the Pfcrt gene related to P. falciparum chloroquine
resistance, including the mixed haplotypes (n = 31).
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double mutant SGKGA (4%, n = 1) (Figure 5).
When both Pfdhfr and Pfdhps haplotypes were jointly
examined, haplotypes could be constructed for 27 sam-
ples. The main haplotypes were the quadruple mutant
haplotypes CNRNI/SGEAA (33%, n = 9) and CNRNI/
AGEAA (30%, n = 8), whereas the quintuple mutant
haplotypes were determined low; CIRNI/AGEAA (4%,
n = 1) and CIRNI/SGKAA (4%, n = 1).
Prevalence of SNPs in Pvmdr1
Only a fraction of samples (n = 47) were sequenced by
alignment of DNA sequence with the wild type Salvador
1 as reference strain and out of these, 39 samples had
satisfactory results. Only a fragment of 784 bp covering
the codons 958, 976 and 1076 of the Pvmdr1 gene had
been sequenced. A novel mutation was identified at
T958M in all samples while F1076L was observed in 37
samples (95%) and Y976F was only identified in two
samples (5%). Including the T958M mutation in con-
structing haplotypes for c958, c976 and c1076, the most
frequent haplotype was the double mutant haplotype
MYL (82%, n = 32), whereas the single mutant MYF
and the triple mutant MFL haplotypes were determined
in 13% (n = 5) and 5% (n = 2) of the cases, respectively
(Figure 6). Finally, novel SNPs were observed in two
samples; one sample was found to contain a TTT to
TCT mutation at c979 (F979S), and an ATG to GTG
mutation at c980 (M980V). Further, one sample con-
tained an AGT to AAT mutation at c1080 (S1080N).
Prevalence of SNPs in Pvdhfr gene
SNPs were observed at c57, c58, c61 in 63 samples and at
c117 in 65 samples respectively. Pvdhfr mutations were
identified at S58R (68%, n = 43) followed by S117N/T
(54%, n = 35) and F57L (11%, n = 7), whereas only wild
type was determined at c61. Haplotypes could be con-
structed for 55 samples and the major haplotypes were
the double mutant FR2TN (47%, n = 26) and wild type
FSTS (27%, n = 15). Single mutant haplotypes FR1TS
(9%, n = 5), FR2TS (4%, n = 2) & FSTT (2%, n = 1) and
double mutant haplotypes L2R1TS (9%, n = 5) & L2STN
(2%, n = 1) were also determined while triple and quad-
ruple mutant haplotypes were not identified (Figure 7).
Discussion
Several therapeutic efficacy studies were carried out
in Nepal to determine the efficacy of currently used
Figure 3 Frequency of haplotypes of Pfmdr1 in samples from
Jhapa and Banke districts in Nepal. Frequency of constructed
haplotypes of SNPs in the Pfmdr1 gene at c86, c184 and c1246
associated with P. falciparum chloroquine resistance (n = 26).
Figure 4 Frequency of haplotypes of Pfdhfr in samples from
Jhapa and Banke districts in Nepal. Frequency of constructed
haplotypes of SNPs in the Pfdhfr gene at c50, c51, c59, c108 and c164
associated with P. falciparum pyrimethamine resistance (n = 32).
Figure 5 Frequency of haplotypes of Pfdhps in samples from
Jhapa and Banke districts in Nepal. Frequency of constructed
haplotypes of SNPs in the Pfdhps gene at c436, c437, c540, c581
and c613 linked with P. falciparum sulphadoxine resistance (n = 28).
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from 1984 to 1990 had shown 38% in vivo resistance
to CQ. Similarly, SP efficacy studies conducted
between 1996 to 2000 showed 57-73% treatment fail-
ures in P. falciparum infections [36]. Contrarily, a trial
performed in 2005 in Jhapa showed only 12% SP treat-
ment failure [26]. In Nepal, changes in anti-malarial
drug policies have been based on declining efficacy of
first line drugs when the therapeutic efficacy fell below
90% [4]. In line with this, AL was introduced against
P. falciparum in 2004 in 13 highly endemic districts.
SP is still the first line of treatment in the other 52
endemic districts, however, ACT will gradually replace
SP in the near future [4].
This study determined CQ and SP resistance at mole-
cular level to explore whether the high level of in vivo
CQ and SP resistance previously found in Nepal result-
ing in the recent policy change, is reflected at molecular
level as well. Polymorphisms related to CQ resistance in
P. falciparum were determined in both Pfcrt and
Pfmdr1. Combined, the Pfcrt mutant haplotypes CVIET
(55%) and SVMNT (42%) were determined in a total of
97% of samples indicating high levels of CQ resistance.
These haplotypes were also the most common haplotype
determined from the Indian state of Assam (33% CVIET
and 62% SVMNT) in 2006 [37].
Studies done in Malawi [38] and Tanzania [39] had
shown the re-emergence of CQ sensitive P. falciparum
populations after the withdrawal of CQ as a first line
drug. However, this was not observed here, most prob-
ably due to the current anti-malarial drug policy of
Nepal which recommends CQ for laboratory uncon-
firmed P. falciparum infection [4]. Regarding Pfmdr-1,
this study found a high prevalence of wild types N86
(67%), Y184 (56%) and D1246 (100%). Further, 35% of
the constructed haplotypes were the haplotype NFD.
This haplotype has previously been implied as a marker
of emerging AL tolerance [35,40]. Therefore, it is impor-
tant to continue the monitoring of this particular mar-
ker in Nepal now with AL as the first-line treatment in
highly endemic areas.
Studies have indicated that Y976F is the most impor-
tant marker of CQ resistance and F1076L of lesser
importance [11,31,41]. The analysis of Pvmdr1 identified
a novel mutation at T958M, which has only been
reported in samples from Madagascar [42] and its role
in CQ resistance is unknown. Likewise, mutation at
Y976F was determined only in two samples (5%). This
suggests the presence of limited prevalence of CQ resis-
tant haplotypes in P. vivax population. Finally, SNPs at
c979, c980 and c1080 were observed, which have not
been described elsewhere and the implications of these
are unknown.
Regarding SP resistance in P. falciparum, SNPs at c51,
c59 and c108 of Pfdhfr were identified. The most fre-
quent mutant haplotype was the double mutated
CNRNI (91%), which was also the most frequent haplo-
type determined at 64% from Jhapa in 2005 [26]. Thus,
it seems that the prevalence of double mutant haplotype
has increased. Furthermore, in 2003/2004, the CNRNI
haplotype was the most frequent haplotype determined
at 50-91% and 74-80% from Utter Pradesh and Assam
in India, respectively [43,44]. Likewise, the triple
mutated CIRNI was detected at low prevalence (6%) in
the current study and in concordance with the previous
study done in Jhapa (prevalence of 10% and 3% in 2002
and 2005 respectively) [26]. Further, CIRNI was also
determined low in samples from Utter Pradesh (5%) and
Figure 6 Frequency of haplotypes of Pvmdr1 in samples from
Jhapa and Banke districts in Nepal. Frequency of constructed
haplotypes of SNPs in the Pvmdr1 gene at c958, c976 and c1076
associated with P. vivax chloroquine resistance (n = 39).
Figure 7 Frequency of haplotypes of Pvdhfr in samples from
Jhapa and Banke districts in Nepal. Frequency of constructed
haplotypes of SNPs in the Pvdhfr gene at c57, c58, c61 and c117
linked with P. vivax pyrimethamine resistance (n = 55).
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consistent prevalence of the triple mutant haplotypes in
the region. For Pfdhps,S G E A A( 3 8 % )a n dA G E A A
(33%), the haplotypes that have been associated with
treatment failure of SP [45] were the most prevalent in
this study. In the study done in Assam in 2003/2004,
SGEAA and AGEAA were determined in 2-6% and 11-
17% of the samples, respectively [43,44]. This may sug-
gest an increase of sulphadoxine resistant haplotypes in
the region.
For Pfdhfr and Pfdhps combined, both quadruple
(double mutations in Pfdhps and Pfdhps) and quintuple
mutations (triple mutations in Pfdhfr and double muta-
tions in Pfdhps) have been associated with treatment
failures [43,46,47]. The present study determined quad-
ruple mutations in 63% of samples. Further, the low pre-
valence (17%) of CNRNI-SGEAA/AGEAA in Assam in
2003 [43,44] may point towards the increase of preva-
lence of quadruple mutations in the region. Thus, this
high prevalence may imply a high risk of SP treatment
failure, which is in concordance with two previous stu-
dies done in Jhapa that recorded 12% and 21% treat-
ment failures of SP [26,48].
Although SP is not used deliberately against P. vivax
infections in Nepal, P. vivax is exposed to SP through
mixed infections and/or incorrect diagnosis [20-22].
Regarding SNPs in the Pvdhfr, the double mutant
FR2TN which is common in Uttar Pradesh (34%) and
Assam (50%) [49], was the major mutant haplotype in
the current study (47%) as well. The triple and quadru-
ple Pvdhfr mutant haplotypes associated with high levels
of in vivo SP resistance [50] were not found, indicating
limited levels of P. vivax SP resistance in the study area.
The SNP patterns observed in Pfcrt, Pfdhfr and Pvdhfr
genes in Nepal are similar to the studies performed in
India, especially in the states that share borders with
Nepal [37,43,49]. This indicates that either the parasites
are under similar drug pressure in both countries or the
free movement of people for work and other purposes
between these countries are responsible for carrying
parasites with similar drug resistance profiles. In this
study, high percentages (85%) of the malaria positive
were identified in males. Similar results were determined
from Jhapa in 2005 (73%) and 2007 (75%) [26,51]. A
study done in 2008 showed that around 37% of patients,
particularly the males, had a history of a recent visit to
India [52]. Although this study did not evaluate this
aspect, it may be the possible cause for the higher per-
centage of infection in males and thus the similar pat-
t e r n so fS N P si nt h er e s i s t a n c eg e n e so fP. falciparum
and P. vivax.
A limitation to the present study is the small sample
size. The majority of the samples collected on glass
slides were found negative by PCR, which may be due
to low parasitemia or misdiagnosis by microscopy or
simply poor success in DNA extraction. Thus, the
results should be interpreted with caution.
Conclusions
This study has determined low molecular prevalence of
resistance to CQ and SP in P. vivax and a high level of
CQ and SP resistance in P. falciparum in a limited
number of samples from two districts in Nepal. There-
fore, CQ is most likely still effective in the treatment of
P. vivax infections, but this remains to be tested in vivo
while the change to ACT against P. falciparum infection
seems justified at molecular level.
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